Xenon Pharmaceuticals Inc. - Special Call Transcript
Ladies and gentlemen, thank you for standing by and welcome to the Xenon Pharmaceuticals Corporate Update Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Jodi Regts. Thank you. Please go ahead.
Thanks, Jimmy. Good morning. Thank you for joining us on the call and webcast to provide a corporate update and discuss this morning's announcement regarding a license and collaboration agreement with Neurocrine Biosciences. Joining me are Dr. Simon Pimstone, Xenon's Chief Executive Officer; and Ian Mortimer, Xenon's President and Chief Financial Officer. Following their comments today, we will open up the call to your questions.
Please be advised that during this call, we will make a number of statements that are forward-looking, including statements regarding the timing of and results from clinical trials and other development activities,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |